UB651
ProductAdalimumab Injection
Strength0.8ml: 40mg
IndicationsRheumatoid arthritis; Juvenile idiopathic arthritis; Ankylosing spondylitis; Psoriasis; Pediatric plaque psoriasis; Crohn's disease; Pediatric Crohn's disease; Uveitis
TherapeuticsImmunology & Inflammation; Rheumatology; Dermatology; Gastroenterology & Hepatology
GMPCN - NMPA; PIC/S; SA - SFDA
RegistrationChina; Saudi Arabia
ModalitiesAntibody
Exclusive Summary
- · Recombinant fully human tumor necrosis factor-α monoclonal antibody, the "Global Drug King" biosimilar with many indications and large sales in the field of autoimmune diseases
- · A total of 648 patients were included in the phase III clinical study, which is a phase III clinical study with a relatively large sample size among similar products in China, and the efficacy and safety have been fully verified
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →